Nachrichten zur Immunic Inc. Aktie

Immunic Inc. (IMUX) ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von innovativen Therapien für chronische Entzündungserkrankungen und Autoimmunerkrankungen…

Immunic Inc (NASDAQ:IMUX) announced a positive outcome from the interim futility analysis of its Phase 3 ENSURE program which is…

Immunic Inc (NASDAQ:IMUX) announced that it is presenting key data for its lead asset vidofludimus calcium at the 40th Congress…

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler joined Proactive to discuss a research update for the companys lead compound...…

Immunic Inc (NASDAQ:IMUX) announced that the first patient has been enrolled in an investigator-sponsored Phase 2 trial of its lead…

Immunic Inc (NASDAQ:IMUX) announced that it will be hosting a Multiple Sclerosis (MS) Research and Development (R&D) Day on September…

…

Immunic Inc (NASDAQ:IMUX) has highlighted clinical and operational progress achieved during the second quarter, which ended June 30, 2024, and…

To mark World Brain Day on July 22, Immunic Inc (NASDAQ:IMUX)s chief scientific officer Hella Kohlhof joined Proactive to discuss…

Biotechnology firm Immunic Inc (NASDAQ:IMUX) announced the appointment of Simona Skerjanec to its board of directors. Skerjanec brings nearly three…

Immunic Inc (NASDAQ:IMUX) told investors it has appointed a former Novartis and Biogen executive as its new chief operating officer to lead internal…

…

…

Immunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset, nuclear receptor related 1 (Nurr1) activator…

Immunic Inc (NASDAQ:IMUX) has published extended data from its Phase 2 EMPhASIS trial of its lead asset vidofludimus calcium in…

Immunic Inc (NASDAQ:IMUX) has received a Notice of Allowance for a composition-of-matter patent covering a specific polymorph of vidofludimus calcium,…

Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its…